Amphastar Pharmaceuticals (AMPH) Total Liabilities (2013 - 2026)
Amphastar Pharmaceuticals (AMPH) posted quarterly Total Liabilities of $874.8 million for Q1 2026, little changed year-over-year from $875.0 million in Q1 2025, and up 4.08% quarter-over-quarter from $840.5 million in Q4 2025.
Amphastar Pharmaceuticals (AMPH) Total Liabilities (2013 - 2026) Analysis & Trends
Amphastar Pharmaceuticals' Total Liabilities history runs 14 years deep, the most recent figure standing at $874.8 million for Q1 2026.
- In Q1 2026, Total Liabilities changed 0.03% year-over-year to $874.8 million; the TTM figure through Mar 2026 stood at $874.8 million (changed 0.03% YoY), while the FY2025 annual figure was $840.5 million, down 0.55% from the prior year.
- Total Liabilities for Q1 2026 stood at $874.8 million, up from $840.5 million in the prior quarter.
- The five-year high for Total Liabilities was $949.5 million in Q3 2023, with the low at $213.3 million in Q4 2022.
- The 5-year median for Total Liabilities is $840.5 million (2025), against an average of $671.4 million.
- The sharpest annual moves came in 2023 and 2024: Total Liabilities soared 328.61% in 2023, then retreated 13.9% in 2024.
- Amphastar Pharmaceuticals' Total Liabilities stood at $213.3 million in 2022, then jumped by 309.46% to $873.5 million in 2023, then declined by 3.24% to $845.2 million in 2024, then declined by 0.55% to $840.5 million in 2025, then grew by 4.08% to $874.8 million in 2026.
- Business Quant data shows AMPH's Total Liabilities at $874.8 million in Q1 2026, $840.5 million in Q4 2025, and $889.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | -21.66 Bn |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | 32.10 Bn |
| 3 | Zoetis | 31.53 Bn | 29.85 Bn | 1.05 Bn | 11.93 Bn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 50.85 Bn |
| 5 | United Therapeutics | 22.13 Bn | 19.47 Bn | 683.80 Mn | 819.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 20.78 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 1.67 Bn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 6.97 Bn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | 2.12 Bn |
| 10 | Amphastar Pharmaceuticals | 942.71 Mn | 652.59 Mn | 93.47 Mn | 975.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 975.61 Mn |
| Mar 31, 2026 | 874.77 Mn |
| Dec 31, 2025 | 840.49 Mn |
| Sep 30, 2025 | 889.48 Mn |
| Jun 30, 2025 | 857.85 Mn |
| Mar 31, 2025 | 874.99 Mn |
| Dec 31, 2024 | 845.17 Mn |
| Sep 30, 2024 | 817.50 Mn |
| Jun 30, 2024 | 778.18 Mn |
| Mar 31, 2024 | 901.96 Mn |
| Dec 31, 2023 | 873.49 Mn |
| Sep 30, 2023 | 949.49 Mn |
| Jun 30, 2023 | 789.03 Mn |
| Mar 31, 2023 | 225.08 Mn |
| Dec 31, 2022 | 213.33 Mn |
| Sep 30, 2022 | 221.53 Mn |
| Jun 30, 2022 | 224.41 Mn |
| Mar 31, 2022 | 236.71 Mn |
| Dec 31, 2021 | 226.01 Mn |
| Sep 30, 2021 | 221.50 Mn |